221 related articles for article (PubMed ID: 12235005)
1. Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain.
Juarez JC; Guan X; Shipulina NV; Plunkett ML; Parry GC; Shaw DE; Zhang JC; Rabbani SA; McCrae KR; Mazar AP; Morgan WT; Doñate F
Cancer Res; 2002 Sep; 62(18):5344-50. PubMed ID: 12235005
[TBL] [Abstract][Full Text] [Related]
2. Peptides derived from the histidine-proline domain of the histidine-proline-rich glycoprotein bind to tropomyosin and have antiangiogenic and antitumor activities.
Doñate F; Juarez JC; Guan X; Shipulina NV; Plunkett ML; Tel-Tsur Z; Shaw DE; Morgan WT; Mazar AP
Cancer Res; 2004 Aug; 64(16):5812-7. PubMed ID: 15313924
[TBL] [Abstract][Full Text] [Related]
3. Histidine-proline rich glycoprotein (HPRG) binds and transduces anti-angiogenic signals through cell surface tropomyosin on endothelial cells.
Guan X; Juarez JC; Qi X; Shipulina NV; Shaw DE; Morgan WT; McCrae KR; Mazar AP; Doñate F
Thromb Haemost; 2004 Aug; 92(2):403-12. PubMed ID: 15269838
[TBL] [Abstract][Full Text] [Related]
4. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
5. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.
Hagedorn M; Zilberberg L; Wilting J; Canron X; Carrabba G; Giussani C; Pluderi M; Bello L; Bikfalvi A
Cancer Res; 2002 Dec; 62(23):6884-90. PubMed ID: 12460903
[TBL] [Abstract][Full Text] [Related]
6. Domain structure and conformation of histidine-proline-rich glycoprotein.
Borza DB; Tatum FM; Morgan WT
Biochemistry; 1996 Feb; 35(6):1925-34. PubMed ID: 8639676
[TBL] [Abstract][Full Text] [Related]
7. The C-terminal domain of canstatin suppresses in vivo tumor growth associated with proliferation of endothelial cells.
He GA; Luo JX; Zhang TY; Hu ZS; Wang FY
Biochem Biophys Res Commun; 2004 May; 318(2):354-60. PubMed ID: 15120609
[TBL] [Abstract][Full Text] [Related]
8. Activated platelets provide a functional microenvironment for the antiangiogenic fragment of histidine-rich glycoprotein.
Thulin A; Ringvall M; Dimberg A; Kårehed K; Väisänen T; Väisänen MR; Hamad O; Wang J; Bjerkvig R; Nilsson B; Pihlajaniemi T; Akerud H; Pietras K; Jahnen-Dechent W; Siegbahn A; Olsson AK
Mol Cancer Res; 2009 Nov; 7(11):1792-802. PubMed ID: 19903770
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE
Oncogene; 2005 Jan; 24(5):790-800. PubMed ID: 15592523
[TBL] [Abstract][Full Text] [Related]
10. Minimal active domain and mechanism of action of the angiogenesis inhibitor histidine-rich glycoprotein.
Dixelius J; Olsson AK; Thulin A; Lee C; Johansson I; Claesson-Welsh L
Cancer Res; 2006 Feb; 66(4):2089-97. PubMed ID: 16489009
[TBL] [Abstract][Full Text] [Related]
11. Evidence of human thrombomodulin domain as a novel angiogenic factor.
Shi CS; Shi GY; Chang YS; Han HS; Kuo CH; Liu C; Huang HC; Chang YJ; Chen PS; Wu HL
Circulation; 2005 Apr; 111(13):1627-36. PubMed ID: 15795324
[TBL] [Abstract][Full Text] [Related]
12. Hypoestoxide, a natural nonmutagenic diterpenoid with antiangiogenic and antitumor activity: possible mechanisms of action.
Ojo-Amaize EA; Nchekwube EJ; Cottam HB; Bai R; Verdier-Pinard P; Kakkanaiah VN; Varner JA; Leoni L; Okogun JI; Adesomoju AA; Oyemade OA; Hamel E
Cancer Res; 2002 Jul; 62(14):4007-14. PubMed ID: 12124334
[TBL] [Abstract][Full Text] [Related]
13. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
[TBL] [Abstract][Full Text] [Related]
14. Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor.
Ramesh R; Mhashilkar AM; Tanaka F; Saito Y; Branch CD; Sieger K; Mumm JB; Stewart AL; Boquoi A; Dumoutier L; Grimm EA; Renauld JC; Kotenko S; Chada S
Cancer Res; 2003 Aug; 63(16):5105-13. PubMed ID: 12941841
[TBL] [Abstract][Full Text] [Related]
15. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice.
Reinmuth N; Liu W; Ahmad SA; Fan F; Stoeltzing O; Parikh AA; Bucana CD; Gallick GE; Nickols MA; Westlin WF; Ellis LM
Cancer Res; 2003 May; 63(9):2079-87. PubMed ID: 12727823
[TBL] [Abstract][Full Text] [Related]
16. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic and antitumoral activity of phenyl-3-(2-chloroethyl)ureas: a class of soft alkylating agents disrupting microtubules that are unaffected by cell adhesion-mediated drug resistance.
Petitclerc E; Deschesnes RG; Côté MF; Marquis C; Janvier R; Lacroix J; Miot-Noirault E; Legault J; Mounetou E; Madelmont JC; C -Gaudreault R
Cancer Res; 2004 Jul; 64(13):4654-63. PubMed ID: 15231678
[TBL] [Abstract][Full Text] [Related]
18. Canstatin-N fragment inhibits in vitro endothelial cell proliferation and suppresses in vivo tumor growth.
He GA; Luo JX; Zhang TY; Wang FY; Li RF
Biochem Biophys Res Commun; 2003 Dec; 312(3):801-5. PubMed ID: 14680836
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic activity of TZT-1027 (soblidotin) on chick chorioallantoic membrane and human umbilical vein endothelial cells.
Watanabe J; Endo Y; Shimada N; Natsume T; Sasaki T; Kobayashi M
In Vivo; 2007; 21(2):297-304. PubMed ID: 17436580
[TBL] [Abstract][Full Text] [Related]
20. Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin.
Morbidelli L; Donnini S; Chillemi F; Giachetti A; Ziche M
Clin Cancer Res; 2003 Nov; 9(14):5358-69. PubMed ID: 14614021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
